FDA Reviews Mifepristone Amid Safety Concerns

The FDA is rushing a political-driven safety review of mifepristone, sparking alarm among medical experts who fear the process is cherry-picking data to justify a predetermined outcome — despite the drug’s two-decade track record of safety and ongoing legal battles over its nationwide mail-order access. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6369b70297c23b50